Potomac Bancshares Q2 net income rises on loan growth; lifts dividend
Reuters2026/07/29 11:22
Overview
US community bank's Q2 net income rose 60% yr/yr, with adjusted EPS up 54%
Company attributes record earnings to loan growth, higher net interest margin, and wealth management income
Quarterly dividend raised 15% from prior quarter to $0.15 per share
Result Drivers
LOAN GROWTH AND INTEREST INCOME - Co said higher loan balances and increased interest income and fees on loans drove net interest income growth, with additional benefit from accelerated deferred loan fee income on a loan payoff
WEALTH MANAGEMENT INCOME - Wealth management income rose due to a new client fee schedule and estate fee income
COMMERCIAL DEPOSIT AND MARKET EXPANSION - Co cited commercial deposit growth and expansion into new and existing markets as strategic priorities, contributing to business development costs and marketing expense increases
Company press release: ID:nPnXj5Bga
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Net Interest Margin |
|
3.76% |
|
Reuters Recommended Reads
July 28 - Camden National Q2 net income rises on loan growth
July 28 - First Busey Q2 adjusted EPS tops estimates on higher wealth management fee
July 28 - Broadway Financial Q2 net income rises on loan and deposit growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst: This 2026 XRP Price Prediction Way Well Go Into the History Books
Bitcoin Red Team Claims Blockstream Ignored Warnings Before Hack
Bitcoin's Weirdest Trader Yet? Fly Brain Makes a Profit
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street -- WSJ